|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SNRNP27 |
Gene summary for SNRNP27 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SNRNP27 | Gene ID | 11017 |
| Gene name | small nuclear ribonucleoprotein U4/U6.U5 subunit 27 | |
| Gene Alias | 27K | |
| Cytomap | 2p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A8K513 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11017 | SNRNP27 | LZE4T | Human | Esophagus | ESCC | 7.30e-14 | 4.27e-01 | 0.0811 |
| 11017 | SNRNP27 | LZE7T | Human | Esophagus | ESCC | 9.57e-12 | 4.83e-01 | 0.0667 |
| 11017 | SNRNP27 | LZE8T | Human | Esophagus | ESCC | 6.08e-09 | 1.36e-01 | 0.067 |
| 11017 | SNRNP27 | LZE20T | Human | Esophagus | ESCC | 3.47e-05 | 1.32e-01 | 0.0662 |
| 11017 | SNRNP27 | LZE22D1 | Human | Esophagus | HGIN | 7.06e-03 | 5.08e-02 | 0.0595 |
| 11017 | SNRNP27 | LZE22T | Human | Esophagus | ESCC | 8.04e-05 | 2.13e-01 | 0.068 |
| 11017 | SNRNP27 | LZE24T | Human | Esophagus | ESCC | 3.99e-17 | 5.24e-01 | 0.0596 |
| 11017 | SNRNP27 | LZE21T | Human | Esophagus | ESCC | 5.25e-04 | 3.59e-01 | 0.0655 |
| 11017 | SNRNP27 | LZE6T | Human | Esophagus | ESCC | 1.46e-10 | 4.65e-01 | 0.0845 |
| 11017 | SNRNP27 | P1T-E | Human | Esophagus | ESCC | 7.17e-08 | 5.34e-01 | 0.0875 |
| 11017 | SNRNP27 | P2T-E | Human | Esophagus | ESCC | 1.85e-26 | 5.86e-01 | 0.1177 |
| 11017 | SNRNP27 | P4T-E | Human | Esophagus | ESCC | 1.05e-20 | 5.74e-01 | 0.1323 |
| 11017 | SNRNP27 | P5T-E | Human | Esophagus | ESCC | 6.32e-26 | 4.83e-01 | 0.1327 |
| 11017 | SNRNP27 | P8T-E | Human | Esophagus | ESCC | 4.92e-23 | 3.68e-01 | 0.0889 |
| 11017 | SNRNP27 | P9T-E | Human | Esophagus | ESCC | 2.19e-15 | 3.08e-01 | 0.1131 |
| 11017 | SNRNP27 | P10T-E | Human | Esophagus | ESCC | 2.74e-42 | 7.42e-01 | 0.116 |
| 11017 | SNRNP27 | P11T-E | Human | Esophagus | ESCC | 5.35e-11 | 4.91e-01 | 0.1426 |
| 11017 | SNRNP27 | P12T-E | Human | Esophagus | ESCC | 1.85e-32 | 4.71e-01 | 0.1122 |
| 11017 | SNRNP27 | P15T-E | Human | Esophagus | ESCC | 8.36e-26 | 5.72e-01 | 0.1149 |
| 11017 | SNRNP27 | P16T-E | Human | Esophagus | ESCC | 9.88e-31 | 5.34e-01 | 0.1153 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
| GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
| GO:0008380113 | Thyroid | PTC | RNA splicing | 273/5968 | 434/18723 | 4.44e-41 | 1.40e-37 | 273 |
| GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0304018 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304019 | Esophagus | HGIN | Spliceosome | 79/1383 | 217/8465 | 3.22e-13 | 7.00e-12 | 5.56e-12 | 79 |
| hsa0304027 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa0304037 | Esophagus | ESCC | Spliceosome | 128/4205 | 217/8465 | 3.31e-03 | 8.79e-03 | 4.50e-03 | 128 |
| hsa030407 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304012 | Liver | Cirrhotic | Spliceosome | 102/2530 | 217/8465 | 5.69e-08 | 9.47e-07 | 5.84e-07 | 102 |
| hsa0304022 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304032 | Liver | HCC | Spliceosome | 122/4020 | 217/8465 | 5.55e-03 | 1.60e-02 | 8.91e-03 | 122 |
| hsa0304016 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304017 | Oral cavity | OSCC | Spliceosome | 123/3704 | 217/8465 | 7.21e-05 | 2.74e-04 | 1.40e-04 | 123 |
| hsa0304026 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| hsa0304036 | Oral cavity | LP | Spliceosome | 106/2418 | 217/8465 | 1.30e-10 | 2.40e-09 | 1.55e-09 | 106 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SNRNP27 | SNV | Missense_Mutation | c.220N>A | p.Glu74Lys | p.E74K | Q8WVK2 | protein_coding | tolerated(0.1) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNRNP27 | SNV | Missense_Mutation | c.292N>A | p.Glu98Lys | p.E98K | Q8WVK2 | protein_coding | tolerated(0.19) | probably_damaging(0.973) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNRNP27 | SNV | Missense_Mutation | rs143382169 | c.124C>T | p.Arg42Cys | p.R42C | Q8WVK2 | protein_coding | deleterious(0) | probably_damaging(0.965) | TCGA-DR-A0ZL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| SNRNP27 | SNV | Missense_Mutation | c.283G>A | p.Gly95Ser | p.G95S | Q8WVK2 | protein_coding | deleterious(0.04) | probably_damaging(0.996) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SNRNP27 | SNV | Missense_Mutation | c.368C>T | p.Ser123Phe | p.S123F | Q8WVK2 | protein_coding | deleterious(0.01) | benign(0.117) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| SNRNP27 | SNV | Missense_Mutation | novel | c.113N>A | p.Arg38Gln | p.R38Q | Q8WVK2 | protein_coding | deleterious(0.03) | benign(0.057) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SNRNP27 | SNV | Missense_Mutation | c.422N>G | p.Met141Arg | p.M141R | Q8WVK2 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-A5-A0GV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| SNRNP27 | SNV | Missense_Mutation | c.83N>A | p.Arg28Gln | p.R28Q | Q8WVK2 | protein_coding | tolerated(0.24) | benign(0) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SNRNP27 | SNV | Missense_Mutation | c.454G>A | p.Asp152Asn | p.D152N | Q8WVK2 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SNRNP27 | SNV | Missense_Mutation | novel | c.428G>A | p.Arg143Gln | p.R143Q | Q8WVK2 | protein_coding | deleterious(0) | benign(0.235) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |